TY - JOUR
T1 - Pharmacokinetics and plasma bactericidal activity of aztreonam in low-birth-weight infants
AU - Likitnukul, S.
AU - McCracken, G. H.
AU - Threlkeld, N.
AU - Darabi, A.
AU - Olsen, K.
PY - 1987
Y1 - 1987
N2 - Aztreonam (30 mg/kg) was administered intravenously every 12 h during week 1 and every 8 h during weeks 2 to 4 of life to 26 low-birth-weight (<2,000 g) infants, and plasma concentration-time curves were measured on two occasions. The pharmacokinetics were described equally well by one-compartment and noncompartment models, and the values on day 1 were similar to those measured during the steady state on days 3 to 6. The mean peak plasma concentrations at completion of the 10-min infusion were from 65 to 83 μg/ml, the higher concentrations being seen in the larger infants. The half-lives of aztreonam ranged from 5.4 to 8.6 h and did not change significantly with birth weight. The median peak and trough plasma bactericidal titer against a strain of Escherichia coli (MBC, 10 μg/ml) was 1:16. Against a strain of Pseudomonas aeruginosa (MBC, 16 μg/ml), the median peak and trough bactericidal titers were 1:8 to 1:16 and 1:4, respectively. The urinary concentrations of aztreonam on day 1 of therapy were from 24 to 460.7 μg/ml (mean ± 1 standard deviation, 254 ± 113 μg/ml).
AB - Aztreonam (30 mg/kg) was administered intravenously every 12 h during week 1 and every 8 h during weeks 2 to 4 of life to 26 low-birth-weight (<2,000 g) infants, and plasma concentration-time curves were measured on two occasions. The pharmacokinetics were described equally well by one-compartment and noncompartment models, and the values on day 1 were similar to those measured during the steady state on days 3 to 6. The mean peak plasma concentrations at completion of the 10-min infusion were from 65 to 83 μg/ml, the higher concentrations being seen in the larger infants. The half-lives of aztreonam ranged from 5.4 to 8.6 h and did not change significantly with birth weight. The median peak and trough plasma bactericidal titer against a strain of Escherichia coli (MBC, 10 μg/ml) was 1:16. Against a strain of Pseudomonas aeruginosa (MBC, 16 μg/ml), the median peak and trough bactericidal titers were 1:8 to 1:16 and 1:4, respectively. The urinary concentrations of aztreonam on day 1 of therapy were from 24 to 460.7 μg/ml (mean ± 1 standard deviation, 254 ± 113 μg/ml).
UR - http://www.scopus.com/inward/record.url?scp=0023226390&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023226390&partnerID=8YFLogxK
U2 - 10.1128/AAC.31.1.81
DO - 10.1128/AAC.31.1.81
M3 - Article
C2 - 3105443
AN - SCOPUS:0023226390
SN - 0066-4804
VL - 31
SP - 81
EP - 83
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
IS - 1
ER -